Riluzole

• Description:

  Riluzole is an anticonvulsant agent and belongs to the family of use-dependent Na+ channel blocker which can also inhibit GABA uptake with an IC50 of 43 μM.

• Product Name Alternative:

  PK 26124

• UNSPSC:

  12352005

• Hazard Statement:

  H300

• Target:

  GABA Receptor; Sodium Channel

• Type:

  Reference compound

• Related Pathways:

  Membrane Transporter/Ion Channel; Neuronal Signaling

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Neurological Disease; Cancer

• Assay Protocol:

  https://www.medchemexpress.com/riluzole.html

• Purity:

  99.80

• Solubility:

  DMSO : 100 mg/mL (ultrasonic) |H2O : 1 mg/mL (ultrasonic; adjust pH to 3 with HCl)

• Smiles:

  NC1=NC2=CC=C(OC(F)(F)F)C=C2S1

• Molecular Formula:

  C8H5F3N2OS

• Molecular Weight:

  234.20

• Precautions:

  H300

• References & Citations:

  [1]He Y, et al. Neuroprotective agent riluzole potentiates postsynaptic GABA (A) receptor function. Neuropharmacology. 2002 Feb;42 (2) :199-209.|[2]Thompson JM, et al. Small-conductance calcium-activated potassium (SK) channels in the amygdala mediate pain-inhibiting effects of clinically available riluzole in a rat model of arthritis pain. Mol Pain. 2015 Aug 28;11:51.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• Citation 01:

  Cell Res. 2022 Jun;32 (6) :555-569.|EMBO Mol Med. 2025 Oct 15.|Free Radic Biol Med. 2024 May 1:217:126-140.|Front Cell Neurosci. 2020 Oct 16;14:575626.|Front Neural Circuits. 2021 Apr 6:15:657445.|J Neurochem. 2025 Oct;169 (10) :e70246.|Nat Commun. 2023 Dec 12;14 (1) :8255.|Nat Neurosci. 2025 Nov 24.|Neurosci Lett. 2021 May 14:753:135846.|Pharmacol Biochem Behav. 2018 May:168:43-50.|Proc Natl Acad Sci U S A. 2023 Oct 10;120 (41) :e2309773120.|Res Sq. 2024 Jul 09.|Adv Sci (Weinh) . 2025 Oct 20:e07908.

• CAS Number:

  [1744-22-5]